Informationen:
Fehler:
ID
19753
Beschreibung
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00389285
Link
https://clinicaltrials.gov/show/NCT00389285
Stichworte
Versionen (1)
- 26.01.17 26.01.17 -
Hochgeladen am
26. Januar 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Carcinoma, Renal Cell NCT00389285
Eligibility Carcinoma, Renal Cell NCT00389285
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Carcinoma, Renal Cell NCT00389285
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Conventional (Clear Cell) Renal Cell Carcinoma
Item
diagnosis of rcc of predominantly clear cell histology
boolean
C0279702 (UMLS CUI [1])
Therapeutic procedure Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
either no prior treatment or a maximum of 2 prior treatment regimens for metastatic rcc that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (vegf) pathway (phase 1 only)
boolean
C0087111 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
systemic therapy Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
at least 1 but no more than 2 prior systemic therapies for metastatic rcc that included no more than 1 therapy targeting the vegf pathway (phase 2 only)
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
Measurable Disease
Item
disease measurable per the response evaluation criteria in solid tumors (recist) (phase 2 only)
boolean
C1513041 (UMLS CUI [1])
Communicable Disease | Systemic disease Significant
Item
presence of acute infection or other significant systemic illness
boolean
C0009450 (UMLS CUI [1])
C0442893 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
C0442893 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
Central Nervous System Involvement
Item
central nervous system involvement by malignancy
boolean
C4050309 (UMLS CUI [1])
Malignant Neoplasms
Item
history of other cancer within 5 years
boolean
C0006826 (UMLS CUI [1])
rIL-21 | sorafenib
Item
previously received ril-21 or sorafenib
boolean
C1831593 (UMLS CUI [1])
C1516119 (UMLS CUI [2])
C1516119 (UMLS CUI [2])